Effect of Fish Oil Supplementation on Hyperlipidemia during Childhood Acute Lymphoblastic Leukemia Treatment – A Pilot Study

References

• Bhojwani D, Darbandi R, Pei D, Ramsey LB, Chemaitilly W, Sandlund JT, Cheng C, Pui C-H, Relling MV, Jeha S, et al. Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. Eur J Cancer. 2014;50(15):2685–2694. doi:10.1016/j.ejca.2014.06.023
   PubMed Web of Science ®Google Scholar
• Mogensen SS, Schmiegelow K, Grell K, Albertsen BK, Wehner PS, Kampmann P, Frandsen TL. Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica. 2017;102(5):e175–e178. doi:10.3324/haematol.2016.160507
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, de Groot-Kruseman HA, Hop WCJ, Boos J, Tissing WJE, van der Sluis IM. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. Haematologica. 2014;99(11):1716–1721. doi:10.3324/haematol.2014.109413
   PubMed Web of Science ®Google Scholar
• Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M, Brunzell JD, Otvos JD, Sallan SE, Rifai N, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood. 1997;89(6):1886–1895. doi:10.1182/blood.V89.6.1886
   PubMed Web of Science ®Google Scholar
• Persson L, Harila-Saari A, Hed IM, Heyman M, Nilsson A, et al. Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents. Pediatr Blood Cancer. 2017;64(10):e26559.
   Web of Science ®Google Scholar
• Steinherz PG. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer. 1994;74(12):3234–3239. doi:10.1002/1097-0142(19941215)74:12 < 3234::aid-cncr2820741224 > 3.0.co;2-1
   PubMed Web of Science ®Google Scholar
• Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, Neale G, Howard SC, Evans WE, Pui C-H, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117(8):2340–2347. doi:10.1182/blood-2010-10-311969
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Müller K, Mogensen SS, Mogensen PR, Wolthers BO, Stoltze UK, Tuckuviene R, Frandsen T. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res. 2017;6:444. doi:10.12688/f1000research.10768.1
   PubMedGoogle Scholar
• Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195–203. doi:10.1097/01.mcg.0000436438.60145.5a
   PubMed Web of Science ®Google Scholar
• Raja RA, Schmiegelow K, Sorensen DN, Frandsen TL. Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017;64(1):32–38. doi:10.1002/pbc.26183
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2008;87(6):1981S–1990S. doi:10.1093/ajcn/87.6.1981S
   PubMed Web of Science ®Google Scholar
• Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189(1):19–30. doi:10.1016/j.atherosclerosis.2006.02.012
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047–2067. doi:10.1016/j.jacc.2011.06.063
   PubMed Web of Science ®Google Scholar
• Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391–409. doi:10.1586/14779072.6.3.391
   PubMedGoogle Scholar
• Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis. 2016;15(1):118. doi:10.1186/s12944-016-0286-4
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jónsson ÓG, Frandsen TL, Wolthers BO, Heyman M, Schmiegelow K, et al. Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study. JCO. 2019;37(19):1638–1646. doi:10.1200/JCO.18.01877
   PubMed Web of Science ®Google Scholar
• Bostrom B. Successful management of extreme hypertriglyceridemia from pegaspargase with omega-3. Pediatr Blood Cancer. 2012;59(2):350. doi:10.1002/pbc.24108
   PubMed Web of Science ®Google Scholar
• Salvador C, Entenmann A, Salvador R, Niederwanger A, Crazzolara R, Kropshofer G. Combination therapy of omega-3 fatty acids and acipimox for children with hypertriglyceridemia and acute lymphoblastic leukemia. J Clin Lipidol. 2018;12(5):1260–1266. doi:10.1016/j.jacl.2018.05.021
   PubMed Web of Science ®Google Scholar
• Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65(5):1645S–1654S. doi:10.1093/ajcn/65.5.1645S
   PubMed Web of Science ®Google Scholar
• Eslick GD, Howe PRC, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136(1):4–16. doi:10.1016/j.ijcard.2008.03.092
   PubMed Web of Science ®Google Scholar
• Lauritzen L, Harsløf LBS, Hellgren LI, Pedersen MH, Mølgaard C, Michaelsen KF. Fish intake, erythrocyte n-3 fatty acid status and metabolic health in Danish adolescent girls and boys. Br J Nutr. 2012;107(5):697–704. doi:10.1017/S0007114511002418
   PubMed Web of Science ®Google Scholar